Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Account Payables (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Change in Account Payables for 13 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 308.79% to $4.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.3 million, a 66.07% decrease, with the full-year FY2025 number at $5.3 million, down 66.07% from a year prior.
  • Change in Account Payables was $4.9 million for Q4 2025 at Madrigal Pharmaceuticals, down from $6.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $37.0 million in Q3 2024 to a low of -$11.7 million in Q1 2023.
  • A 5-year average of $2.4 million and a median of $2.4 million in 2021 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: surged 5463.49% in 2021, then plummeted 935.93% in 2023.
  • Madrigal Pharmaceuticals' Change in Account Payables stood at $11.0 million in 2021, then tumbled by 51.93% to $5.3 million in 2022, then soared by 118.24% to $11.5 million in 2023, then tumbled by 120.58% to -$2.4 million in 2024, then surged by 308.79% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Change in Account Payables are $4.9 million (Q4 2025), $6.0 million (Q3 2025), and -$4.1 million (Q2 2025).